Stefano R. Kim - Publications

Ezabenlimab with induction chemotherapy and adaptive chemoradiotherapy in stage 3 squamous cell anal carcinoma - Authors' reply.

Journal: The Lancet. Oncology

Published: January 12, 2026

Induction chemotherapy followed by chemoradiotherapy in patients with locally advanced anal cancers: The PRODIGE 85-FFCD 1804-KANALRAD trial.

Journal: Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver

Published: October 27, 2025

Ezabenlimab and induction chemotherapy followed by adaptive chemoradiotherapy in patients with stage 3 squamous cell anal carcinoma (INTERACT-ION): an open-label, single-arm, phase 2 trial.

Journal: The Lancet. Oncology

Published: August 08, 2025

Clinical and biological determinants of multimodal metronomic chemotherapy efficacy in chemo-refractory gastrointestinal cancers.

Journal: International journal of cancer

Published: March 30, 2025

Patients with Colorectal Cancer and BRAFV600E-Mutation in Argentina: A Real-World Study-The EMOGI-CRC01 Study.

Journal: Cancers

Published: January 19, 2025

Systemic Therapy for Stage I-III Anal Squamous Cell Carcinoma: ASCO Guideline.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Published: December 16, 2024

Resection of colorectal liver metastases with second-line aflibercept plus FOLFIRI: Results from the RESECTION prospective French cohort.

Journal: European journal of cancer (Oxford, England : 1990)

Published: July 12, 2024

BRAF + EGFR +/- MEK inhibitors after immune checkpoint inhibitors in BRAF V600E mutated and deficient mismatch repair or microsatellite instability high metastatic colorectal cancer.

Journal: European journal of cancer (Oxford, England : 1990)

Published: May 30, 2024

Stanniocalcin 1 in Patients with Refractory Colorectal Cancer Treated with Regorafenib: A Post Hoc Biomarker Analysis of the TEXCAN and CORRECT Trials.

Journal: Cancer research communications

Published: April 28, 2024

A multicenter study evaluating efficacy of immune checkpoint inhibitors in advanced non-colorectal digestive cancers with microsatellite instability.

Journal: European journal of cancer (Oxford, England : 1990)

Published: November 18, 2023

Atezolizumab plus modified docetaxel, cisplatin, and fluorouracil as first-line treatment for advanced anal cancer (SCARCE C17-02 PRODIGE 60): a randomised, non-comparative, phase 2 study.

Journal: The Lancet. Oncology

Published: November 07, 2023

Durable response of lung carcinoma patients to EGFR tyrosine kinase inhibitors is determined by germline polymorphisms in some immune-related genes.

Journal: Molecular cancer

Published: June 07, 2023